XML 44 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Information (Tables)
 6 Months Ended
Mar. 29, 2019
Segment Reporting [Abstract]  
Schedule of Total Revenues, Segment Operating Profit and Total Asset for Reporting Segment
The following tables present total revenues and segment operating profit from continuing operations for each reportable segment (in thousands) and includes a reconciliation of segment operating profit to total U.S. GAAP operating profit by including certain corporate-level expenses, Restructuring and other charges and transaction and integration costs (in thousands). Prior period information has been recast to reflect the current period presentation.
 
For the Three Months Ended
 
For the Six Months Ended
 
March 29, 2019
 
March 30, 2018
 
March 29, 2019
 
March 30, 2018
Revenues from External Customers:
 
 
 
 
 
 
 
Aerospace, Technology and Nuclear
$
1,059,508

 
$
923,905

 
$
2,094,537

 
$
1,634,780

Buildings, Infrastructure and Advanced Facilities
2,032,088

 
1,946,390

 
4,080,847

 
3,019,514

              Total
$
3,091,596

 
$
2,870,295

 
$
6,175,384

 
$
4,654,294

 
For the Three Months Ended
 
For the Six Months Ended
 
March 29, 2019
 
March 30, 2018
 
March 29, 2019
 
March 30, 2018
Segment Operating Profit:
 
 
 
 
 
 
 
Aerospace, Technology and Nuclear
$
73,831

 
$
52,458

 
$
145,982

 
$
113,524

Buildings, Infrastructure and Advanced Facilities
172,689

 
144,755

 
332,148

 
211,615

Total Segment Operating Profit
246,520

 
197,213

 
478,130

 
325,139

Other Corporate Expenses (1)
(49,901
)
 
(47,133
)
 
(121,149
)
 
(96,361
)
Restructuring and Other Charges
(93,938
)
 
(76,473
)
 
(141,171
)
 
(92,200
)
Transaction Costs
—

 
(4,852
)
 
—

 
(72,493
)
Total U.S. GAAP Operating Profit
102,681

 
68,755

 
215,810

 
64,085

Total Other (Expense) Income, net (2)
9,151

 
(20,104
)
 
(11,789
)
 
(22,137
)
Earnings from Continuing Operations Before Taxes
$
111,832

 
$
48,651

 
$
204,021

 
$
41,948

(1)
Other corporate expenses include costs that were previously allocated to the ECR segment prior to discontinued operations presentation in connection with the ECR sale in the approximate amounts of $6.4 million for the three-month periods ended March 29, 2019 and March 30, 2018, respectively, and $12.8 million for the six-month periods ended March 29, 2019 and March 30, 2018, respectively. Other corporate expenses also include intangibles amortization of $18.7 million and $18.2 million for the three-month periods ended March 29, 2019 and March 30, 2018, respectively and $37.3 million and $29.8 million for the six-month periods ended March 29, 2019 and March 30, 2018, respectively.
(2)
Includes gain on the settlement of the CH2M retiree medical plans of $32.4 million and $34.6 million and the amortization of deferred financing fees related to the CH2M acquisition of $0.5 million and $1.0 million for the three- and six-month periods ended March 29, 2019, as well as amortization of deferred financing fees related to the CH2M acquisition of $0.5 million and $0.7 million for the three- and six-month periods ended March 30, 2018.